VIDEO: ‘No significant difference’ in cardiovascular events with JAKs vs. anti-TNF for IBD
Click Here to Manage Email Alerts
Key takeaways:
- Major adverse cardiovascular events occurred among 1.7% of patients on JAK inhibitors vs. 1.9% on anti-TNF therapy.
- Among those aged 65 years and older, 5.3% vs. 6.4% developed cardiovascular events.
PHILADELPHIA — Use of Janus kinase inhibitors did not increase the risk for major cardiovascular or thromboembolic events among patients with inflammatory bowel disease compared with anti-tumor necrosis factor therapy, data showed.
To compare the risk for major adverse cardiovascular events (MACE) and venous thromboembolism (VTE) within 1 year of initiating treatment with Janus kinase (JAK) inhibitors or anti-TNF agents, Saqr Alsakarneh, MD, a third-year resident at the University of Missouri-Kansas City School of Medicine, and colleagues conducted a retrospective cohort study of adult patients with IBD.
They used the TriNetX database to identify 3,740 patients on JAK inhibitors (mean age, 43.1 years; 48.9% women), who were matched 1:1 with 3,740 patients on anti-TNF therapy (mean age, 43 years; 48.9% women). The researchers performed additional subgroup analyses based on age, sex and IBD type.
According to results presented at the ACG Annual Scientific Meeting, 1.76% of patients on JAK inhibitors developed MACE compared with 1.94% on anti-TNF agents (adjusted HR = 0.99; 95% CI, 0.69-1.42), with similar risk reported for VTE (aHR = 0.9; 95% CI, 0.61-1.32).
“Our results showed that there was no significant difference in the risk for MACE or VTE between the JAK inhibitor group and the anti-TNF group,” Alsakarneh told Healio.
Among those aged 65 years and older, 5.3% vs. 6.4%, respectively, developed MACE (aHR = 0.83; 95% CI, 0.49-1.43). The researchers reported no differences based on IBD type.
“JAK inhibitors do not increase the risk for cardiovascular or thromboembolic events compared to anti-TNF therapy in patients with IBD, even in older patients and adults older than 65 years,” Alsakarneh said. “These findings really provide the assurance for clinicians prescribing JAK inhibitors, though further prospective studies are needed to confirm these results.”
Collapse
Alsakarneh S, et al. Major adverse cardiovascular events in patients with IBD taking anti-TNF vs. JAK inhibitors: A propensity matched cohort analysis. Presented at: ACG Annual Scientific Meeting; Oct. 25-30, 2024; Philadelphia (hybrid meeting).
Read more about
Click Here to Manage Email Alerts